Optimising Asparaginase Use and Managing Hypersensitivity in Australasia—A Clinical Practice Guideline From the Australian and New Zealand Children's Haematology/Oncology Group

Asparaginase is a critical component of modern multi-agent chemotherapy regimens for paediatric acute lymphoblastic leukaemia and lymphoblastic lymphoma, with inadequate exposure leading to inferior patient outcomes.

Citation:
O'Connor MJ, Martin M, Trinder SM, ……. Kotecha RS, Cross S. Optimising Asparaginase Use and Managing Hypersensitivity in Australasia—A Clinical Practice Guideline From the Australian and New Zealand Children's Haematology/Oncology Group. J Paediatr Child Health. 2026.

Keywords:
Child disability; asparaginase; hypersensitivity, cancer

Abstract:
Asparaginase is a critical component of modern multi-agent chemotherapy regimens for paediatric acute lymphoblastic leukaemia and lymphoblastic lymphoma, with inadequate exposure leading to inferior patient outcomes.